Abstract
CD40 ligand (CD40L; CD154) is a transmembrane protein expressed on the surface of activated T cells, particularly on CD4 T cells, that stimulates CD40-dependent activation of antigen-presenting cells, resulting in enhancement of T cell and antibody responses. Soluble multimeric forms of CD40L (sCD40L) act as an effective adjuvant to enhance vaccine immunogenicity. We previously developed a Her2/Neu-LAMP DNA vaccine based on our proprietary UNITE࣪ (UNiversal Intracellular Targeted Expression) platform, which fuses a tumor-associated antigen with lysosomal associated membrane protein 1 (LAMP-1). To increase T cell responses induced by this vaccine, we developed a bicistronic DNA construct in which both the tumor antigen (Her2) fused with LAMP and sCD40L were expressed separately. Secretion of CD40L was confirmed by transient transfection of 293T cells with plasmid DNA followed by ELISA for sCD40L in the cell culture supernatant. Intradermal vaccination of mice with bicistronic Her2-LAMP-sCD40L elicited significantly enhanced Her2-specific T cell and antibody responses compared with mice immunized with Her2-LAMP DNA. Intracellular staining revealed that inclusion of sCD40L in the vaccine induced potent antigen specific T cell IFNγ production, primarily in CD4 T cells. Furthermore, in a murine TSA breast cancer model, Her2-LAMP-sCD40L significantly inhibited tumor growth and prolonged survival in a therapeutic vaccine setting, suggesting that this novel bicistronic vaccine is an effective strategy to promote anti-tumor efficacy in vivo. Ongoing studies are aimed at exploring vaccine-induced changes within the tumor microenvironment, including cytokine profiles, expression of PD-1/PD-L1, and effect on myeloid derived suppressor cells and NK cells. This new approach in bicistronic DNA vaccine design using the UNITE࣪ platform may provide future therapeutic benefit for multiple Her2-expressing cancer types. Citation Format: Wei Shen, Renhuan Xu, Yun-Ting Kao, Mohan Karkada, Teri Heiland. Harnessing soluble CD40L to enhance anti-tumor efficacy of Her2-LAMP DNA vaccine using UNITE࣪ platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3553.